查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2023525

微生物組分析市場分析及預測（至2035年）：依類型、產品類型、服務、技術、組件、應用、流程及最終用戶分類

Microbiome Analytics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球微生物組分析市場預計將從2025年的14億美元成長到2035年的38億美元，複合年成長率（CAGR）為10.9%。預計到2026年，微生物組分析市場每年將處理超過2,500萬個樣本。醫療保健領域佔其應用的55%。北美以43%的市佔率領先。人工智慧驅動的分析平台正以35%的複合年成長率成長。研究表明，腸道微生物組研究佔市場佔有率的60%。 2030年，基於微生物組數據的個人化營養解決方案預計將覆蓋全球8,000萬用戶。

隨著越來越多的研究凸顯微生物組在人類健康和疾病治療中的重要作用，治療性研究正推動相關領域的發展。製藥和生物技術公司正投資於微生物組為基礎的治療方法，以開發針對多種疾病的創新解決方案。對人體內微生物相互作用的深入了解正在推動個人化醫療的進步。研究機構也致力於開發基於微生物組分析的標靶治療。隨著對先進治療方案的需求不斷成長，微生物組分析正成為整個醫療保健產業藥物發現和開發過程中不可或缺的工具。

市場區隔
類型 腸道微生物群、口腔微生物群、皮膚微生物群、陰道微生物群及其他
產品 儀器、試劑盒及試劑、軟體及其他
服務 定序服務、數據分析服務、諮詢服務等。
科技 16S rRNA定序、元基因組定序、總體轉錄組定序等。
成分 硬體、軟體、服務及其他
目的 治療、診斷、研究和開發以及其他
過程 樣品製備、定序、數據分析及其他相關任務。
最終用戶 製藥公司、生技公司、學術和研究機構以及其他

元基因組定序因其能夠提供微生物群落的全面資訊而迅速普及。該技術能夠對環境樣本中的遺傳物質進行詳細分析，並準確鑑定微生物。定序技術和數據分析工具的不斷進步正在提高效率和準確性。隨著微生物組科學研究的拓展，元基因組定序正成為理解複雜生物系統的關鍵技術。其在醫療保健、農業和環境監測等領域的應用正推動著該技術在眾多產業中蓬勃發展並不斷擴大應用範圍。

區域概覽

截至2025年，北美將引領微生物組分析市場，這主要得益於其強大的研究能力以及醫療保健和製藥行業日益成長的應用需求。美國在微生物組研究領域投入巨資，用於疾病診斷和藥物研發，因此在該市場中佔領先地位。先進的實驗室和生物技術公司的存在正在加速創新。對個人化醫療日益成長的需求以及人們對腸道健康的意識提升，進一步推動了微生物組分析技術的應用。此外，政府資助和臨床研究舉措也為市場成長提供了支持，使北美成為成長最快的區域市場。

亞太地區有望成為醫療保健領域成長最快的地區，活性化投資和研究活動的增加。中國和印度等國家正著力研發以微生物組為基礎的治療方法和診斷技術。預防醫學意識的提高和生物技術行業的擴張正在推動市場需求。此外，政府的支持和醫療基礎設施的改善也加速了相關技術的應用。研究機構與行業相關人員之間合作的加強進一步促進了成長，使亞太地區成為全球成長最快的地區。

主要趨勢和促進因素

人們對基於微生物組的醫療保健解決方案越來越感興趣：

由於人們對基於微生物組的醫療保健解決方案的興趣日益濃厚，微生物組分析市場正在蓬勃發展。研究表明，微生物組在人類健康中扮演著至關重要的角色，影響著免疫、消化和疾病的發展。醫療保健機構正在利用微生物組數據開發個人化治療方法和診斷方法。慢性病盛行率的上升進一步推動了先進分析工具的需求。隨著精準醫療的普及，微生物組分析正成為了解患者個別健康狀況和改善治療效果的關鍵要素。

定序和生物資訊學技術的進步：

定序和生物資訊技術的進步正在推動市場成長。次世代定序（NGS）技術能夠對微生物群落進行高速、高精度的詳細分析。改良的生物資訊工具能夠有效率地處理和解讀大規模微生物組資料集。雲端平台增強了數據的可訪問性，並促進了研究人員之間的合作。計算生物學的持續創新正在改進微生物組相互作用的預測模型。隨著這些技術的進步，微生物組分析有望擴展到醫療保健、製藥和營養等產業。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興科技的發展趨勢
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 腸道微生物組
    • 口腔微生物組
    • 皮膚微生物組
    • 陰道微生物組
    • 其他
  • 市場規模及預測：依產品分類
    • 裝置
    • 試劑盒和試劑
    • 軟體
    • 其他
  • 市場規模及預測：依服務分類
    • 定序服務
    • 數據分析服務
    • 諮詢服務
    • 其他
  • 市場規模及預測：依技術分類
    • 16S rRNA測序
    • 元基因組體定序
    • 總體轉錄組組序列
    • 其他
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
    • 其他
  • 市場規模及預測：依應用領域分類
    • 治療藥物
    • 診斷
    • 研究與開發
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 學術和研究機構
    • 其他
  • 市場規模及預測：依製程分類
    • 樣品製備
    • 定序
    • 數據分析
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Illumina
  • Thermo Fisher Scientific
  • QIAGEN
  • Bio-Rad Laboratories
  • Agilent Technologies
  • Becton Dickinson
  • Danaher Corporation
  • PerkinElmer
  • F. Hoffmann-La Roche
  • Eurofins Scientific
  • Charles River Laboratories
  • Merck KGaA
  • Novogene
  • Zymo Research
  • Second Genome
  • CosmosID
  • Enterome
  • Microbiome Insights
  • BiomeSense
  • Diversigen

第9章 關於我們

簡介目錄
Product Code: GIS34485

The global microbiome analytics market is projected to grow from $1.4 billion in 2025 to $3.8 billion by 2035, at a compound annual growth rate (CAGR) of 10.9%. The microbiome analytics market is projected to process over 25 million samples annually by 2026. Healthcare applications account for 55% of usage. North America leads with 43% share. AI-driven analytics platforms are growing at 35% CAGR. Gut microbiome studies represent 60% of research focus. By 2030, personalized nutrition solutions based on microbiome data are expected to reach 80 million users globally.

Therapeutics is leading growth as increasing research highlights the role of microbiomes in human health and disease treatment. Pharmaceutical and biotechnology companies are investing in microbiome-based therapies to develop innovative solutions for various conditions. The growing understanding of microbial interactions within the human body is supporting advancements in personalized medicine. Research institutions are also focusing on developing targeted treatments based on microbiome analysis. As demand for advanced therapeutic solutions increases, microbiome analytics is becoming a critical tool in drug discovery and development processes across the healthcare industry.

Market Segmentation
TypeGut Microbiome, Oral Microbiome, Skin Microbiome, Vaginal Microbiome, Others
ProductInstruments, Kits and Reagents, Software, Others
ServicesSequencing Services, Data Analysis Services, Consulting Services, Others
Technology16S rRNA Sequencing, Metagenomic Sequencing, Metatranscriptomic Sequencing, Others
ComponentHardware, Software, Services, Others
ApplicationTherapeutics, Diagnostics, Research and Development, Others
ProcessSample Preparation, Sequencing, Data Analysis, Others
End UserPharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Others

Metagenomic sequencing is growing rapidly due to its ability to provide comprehensive insights into microbial communities. This technology allows detailed analysis of genetic material from environmental samples, enabling accurate identification of microorganisms. Continuous advancements in sequencing techniques and data analysis tools are improving efficiency and accuracy. As research in microbiome science expands, metagenomic sequencing is becoming an essential technology for understanding complex biological systems. Its applications in healthcare, agriculture, and environmental monitoring are driving strong growth and increasing adoption across multiple industries.

Geographical Overview

North America dominates the microbiome analytics market in 2025 due to strong research capabilities and increasing adoption in healthcare and pharmaceuticals. The United States leads with significant investments in microbiome research for disease diagnosis and drug development. The presence of advanced laboratories and biotechnology companies accelerates innovation. Growing demand for personalized medicine and increasing awareness about gut health further drive adoption. Additionally, government funding and clinical research initiatives support growth, making North America the highest growing regional market.

Asia-Pacific is expected to be the fastest growing region due to rising healthcare investments and increasing research activities. Countries like China and India are focusing on microbiome-based therapies and diagnostics. Growing awareness about preventive healthcare and expanding biotechnology sector drive demand. Additionally, government support and improving healthcare infrastructure accelerate adoption. Increasing collaborations between research institutions and industry players further boost growth, making Asia-Pacific the fastest growing region globally.

Key Trends and Drivers

Growing Interest in Microbiome-Based Healthcare Solutions:

The Microbiome Analytics Market is growing due to increasing interest in microbiome-based healthcare solutions. Research has shown that microbiomes play a critical role in human health, influencing immunity, digestion, and disease development. Healthcare providers are leveraging microbiome data to develop personalized treatments and diagnostics. The rising prevalence of chronic diseases is further driving demand for advanced analytical tools. As precision medicine gains traction, microbiome analytics is becoming a key component in understanding patient-specific health conditions and improving treatment effectiveness.

Advancements in Sequencing and Bioinformatics Technologies:

Technological advancements in sequencing and bioinformatics are driving market growth. Next-generation sequencing (NGS) technologies enable detailed analysis of microbial communities at high speed and accuracy. Improved bioinformatics tools allow efficient processing and interpretation of large microbiome datasets. Cloud-based platforms are enhancing data accessibility and collaboration among researchers. Continuous innovation in computational biology is improving predictive modeling of microbiome interactions. As these technologies advance, microbiome analytics is expected to expand across healthcare, pharmaceuticals, and nutrition industries.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Strategic Recommendations
  • 1.5 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Technologies Landscape
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Gut Microbiome
    • 4.1.2 Oral Microbiome
    • 4.1.3 Skin Microbiome
    • 4.1.4 Vaginal Microbiome
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Kits and Reagents
    • 4.2.3 Software
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Sequencing Services
    • 4.3.2 Data Analysis Services
    • 4.3.3 Consulting Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 16S rRNA Sequencing
    • 4.4.2 Metagenomic Sequencing
    • 4.4.3 Metatranscriptomic Sequencing
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Therapeutics
    • 4.6.2 Diagnostics
    • 4.6.3 R&D
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 Academic & Research Institutes
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Sample Preparation
    • 4.8.2 Sequencing
    • 4.8.3 Data Analysis
    • 4.8.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Process
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Process
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Process
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Process
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Process
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Process
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Process
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Process
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Process
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Process
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Process
    • 5.4.6 Rest of APAC
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Process
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Process
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Process
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Process
    • 5.5.4 Italy
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Process
    • 5.5.5 Rest of Europe
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Process
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Process
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Process
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Process
    • 5.6.4 Rest of MEA
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Process

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Illumina
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 QIAGEN
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bio-Rad Laboratories
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Agilent Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Becton Dickinson
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Danaher Corporation
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 PerkinElmer
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 F. Hoffmann-La Roche
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Eurofins Scientific
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Charles River Laboratories
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Merck KGaA
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Novogene
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Zymo Research
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Second Genome
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 CosmosID
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Enterome
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Microbiome Insights
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 BiomeSense
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Diversigen
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us